Ignacio N Retamal
Overview
Explore the profile of Ignacio N Retamal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
72
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Munoz-Medel M, Pinto M, Goralsky L, Caceres M, Villarroel-Espindola F, Manque P, et al.
Front Oncol
. 2024 May;
14:1403089.
PMID: 38807771
() is a gram-negative oral pathogen associated with chronic periodontitis. Previous studies have linked poor oral health and periodontitis with oral cancer. Severe cases of periodontal disease can result in...
2.
Pinto M, Munoz-Medel M, Retamal I, Bravo M, Latapiat V, Cordova-Delgado M, et al.
Int J Mol Sci
. 2023 Jan;
24(1).
PMID: 36613445
Recently, the combination of chemotherapy plus nivolumab (chemo-immunotherapy) has become the standard of care for advanced-stage gastric cancer (GC) patients. However, despite its efficacy, up to 40% of patients do...
3.
Bendek M, Canedo-Marroquin G, Realini O, Retamal I, Hernandez M, Hoare A, et al.
Int J Mol Sci
. 2021 Nov;
22(21).
PMID: 34769262
Periodontitis is a chronic inflammatory immune disease associated with a dysbiotic state, influenced by keystone bacterial species responsible for disrupting the periodontal tissue homeostasis. Furthermore, the severity of periodontitis is...
4.
Cordova-Delgado M, Bravo M, Cumsille E, Hill C, Munoz-Medel M, Pinto M, et al.
BMC Cancer
. 2021 Sep;
21(1):1030.
PMID: 34525956
Background: Fluoropyrimidine plus platinum chemotherapy remains the standard first line treatment for gastric cancer (GC). Guidelines exist for the clinical interpretation of four DPYD genotypes related to severe fluoropyrimidine toxicity...
5.
Foncea C, von Bischhoffshausen K, Teuber C, Ramirez H, Goni I, Sanchez C, et al.
Rev Med Chil
. 2021 Jan;
148(7):983-991.
PMID: 33399683
Medication-related osteonecrosis of the jaw is a disease where there is necrotic bone exposed or that can be explored by means of a fistula in the maxillofacial region. It has...
6.
Pinto M, Cordova-Delgado M, Retamal I, Munoz-Medel M, Loreto Bravo M, Duran D, et al.
Cancers (Basel)
. 2020 Jul;
12(7).
PMID: 32664343
Gastric cancer (GC) is a complex and heterogeneous disease. In recent decades, The Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) defined GC molecular subtypes. Unfortunately, these...
7.
Calderillo G, Munoz-Medel M, Carbajal E, Cordova-Delgado M, Duran D, Retamal I, et al.
JCO Glob Oncol
. 2020 Apr;
6:647-657.
PMID: 32324433
Purpose: Like other malignancies, GI stromal tumors (GIST) are highly heterogeneous. This not only applies to histologic features and malignant potential, but also to geographic incidence rates. Several studies have...
8.
Cordova-Delgado M, Pinto M, Retamal I, Munoz-Medel M, Bravo M, Fernandez M, et al.
Cancers (Basel)
. 2019 Sep;
11(9).
PMID: 31480291
Gastric cancer (GC) is a heterogeneous disease. This heterogeneity applies not only to morphological and phenotypic features but also to geographical variations in incidence and mortality rates. As Chile has...
9.
Pinto M, Munoz Medel M, Carrillo D, Retamal I, Loreto Bravo M, Valenzuela Y, et al.
Horm Cancer
. 2018 Nov;
10(1):3-10.
PMID: 30465145
Neuroendocrine tumors (NETs) are relatively rare and highly heterogeneous neoplasms. Despite this, recent studies from North America and Central Europe have suggested an increase in incidence. In Latin America, NET...
10.
Owen G, Pinto M, Retamal I, Fernadez M, Cisternas B, Mondaca S, et al.
Medicine (Baltimore)
. 2018 Apr;
97(16):e0419.
PMID: 29668600
Trial Registration: ClinicalTrials.gov Identifier: NCT03158571, Registered on May 18, 2017.